I wish I had High-Yield Urology at the start of my residency The Johns Hopkins Brady Urological Institute. It is a great preparation tool for grand rounds and didactics. By adding your own notes in the margins you can tailor it for your own rapid review before In-Service and Boards. highyieldurology.com

🚨SWOG S1011: Standard vs Extended LND for MIBC NEJM 🇺🇸🇨🇦 RCT, 592 pts w/ T2-4 N0-2 MIBC undergoing RC ➡️ sLND vs eLND ➡️ 5 yr DFS (56 vs 60%) & OS (63 vs 59%) were similar (p>0.05) ➡️ G3-5 AEs in 90 days were ⬆️ w/ eLND (44 vs 55%, p = 0.01) nejm.org/doi/full/10.10…

☝️month to go!

🚨 BALANCE NEJM 🌎🌍🌏 RCT, 3608 hospitalized pts w/ bacteremia (MC bacteria E. Coli 44%; MC source urinary tract 42%) ➡️ 7 vs. 14 days of abx ➡️ 7d was non-inferior re: 90d mortality, resistant colonization, Abx-related AEs (p > 0.05 all) ✅ nejm.org/doi/full/10.10…

🚨 High-Yield Urology 2025 Now Available! ✅ 8 new/updated guideline summaries ✅ 15 new RCTs ✅ 50 new testing pearls ✅ 15% off orders of 5+ books w/ code PROGRAM @uro_res @uroresidency @urologylist @_backtableuro Amer. Urol. Assn. ⁦ABU⁩ highyieldurology.com

Best of luck to all those heading to Raleigh to take down the ABU Oral Boards this week!

Under 4️⃣ months to go until ABU Part I Boards! Great time to start preparing with High-Yield Urology 2025!

JUST IN: U.S. FDA expands Lu-PSMA metastatic castration-resistant prostate cancer indication: now in Taxane-Naive population. Approval based on PSMAfore trial open Dana-Farber Lank Center for Genitourinary Oncology -rPFS 9.3 vs. 5.6mos (HR: 0.41) -OS HR 0.91 Through ASCO FDA alerts.

Big win for bladder cancer care! U.S. FDA approves neoadjuvant + adjuvant durvalumab (NIAGARA trial) in MIBC! Chemo ➕ immunotherapy before surgery. Immunotherapy after. PFS & OS both improved. Proud to be one of investigator of this milestone! #BladderCancer #Immunotherapy

🚨 AUA/SUFU Guideline Update: Microhematuria 👉 refined risk stratification, diagnosis, and surveillance recommendations 👏 ⁦Daniel Barocas⁩ & Team ⁦Amer. Urol. Assn.⁩ ⁦SUFU⁩ ⁦ABU⁩ auajournals.org/doi/10.1097/JU…

🚨BARCODE1 ⁦NEJM⁩ 🇬🇧 population-based prostate cancer screening using top decile of saliva-based DNA “Polygenic Risk Score” as indication for further evaluation with MRI + biopsy nejm.org/doi/full/10.10…

⏳T-minus 3️⃣ months until ABU Part I Boards ➡️ great time to start your exam prep with the fully updated 2025 edition of High-Yield Urology 🚀

Congratulations to all the newly ABU Board Certified urologists! An enormous achievement many years in the making 👏🍾

⏳T-minus 2️⃣ months until ABU Part I Boards ➡️ great time to grab the fully updated 2025 edition of High-Yield Urology 🚀 highyieldurology.com

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

JUST IN: U.S. FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer! Approval based on ENVISION NCT05243550 trial ! Dana-Farber Lank Center for Genitourinary Oncology Amer. Urol. Assn.

And then there was ☝️month until ABU Part I Boards!

📢 Big win for a rare kidney cancer subtype! In HLRCC-associated papillary RCC, bevacizumab + erlotinib delivered a 72% response rate and median PFS of 21.1 months. 🧬 Germline FH-mutated pRCC finally gets a targeted shot. #Oncology #RCC #HLRCC #KidneyCancer #PrecisionMedicine

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr OncoAlert Annals of Oncology astrazeneca.com/media-centre/p…